In early studies in mouse models of metastatic breast cancers, RT combined with an inhibitor of cytotoxic T-lymphocyte associated protein-4 (CTLA-4), a representative negative immune checkpoint, demonstrated a significant survival benefit compared to RT alone. This evidence concerns the gene CTLA4 and breast cancer.